Loading stock data…
TLSI
$3.55+0.21 (+6.35%)
Market OpenUpdated 12:12 PM EDT
TriSalus Life Sciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TriSalus Life Sciences, Inc. in the Healthcare sector is trading at $3.55 with a market capitalization of $195M. Wall Street consensus targets $8.80 (5 analysts), implying a +147.7% move over the next 12 months. The stock is currently 55% below its 52-week high of $7.95, remaining 27.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +147.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.90M↓ | $13.21M↑ | $11.57M↑ | $11.21M↑ | $9.17M |
| Gross Profit | $7.67M↓ | $11.44M↑ | $9.66M↑ | $9.41M↑ | $7.67M |
| Operating Income | -$8.41M↓ | -$3.27M↑ | -$9.01M↓ | -$7.33M | -$7.33M |
| Net Income | $1.54M↑ | -$9.75M↑ | -$10.81M↓ | -$8.29M↑ | -$10.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$195.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-213.27%
Volume
Today's trading volume
165,569
Recent News
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.
TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of TriSalus Life Sciences, Inc.'s Q1 2026 earnings call
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of +12.50% and -15.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
TriSalus Life Sciences Inc. (NASDAQ:TLSI) is one of the best fast growing penny stocks to buy right now. On May 4, TriSalus Life Sciences initiated patient enrollment for the PREDICTT clinical trial, a prospective study evaluating its proprietary Pressure-Enabled Drug Delivery/PEDD technology in patients with primary or metastatic liver tumors. Conducted at The University of […]